Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L21 pseudogene 108 (RPL21P108) is a processed pseudogene, meaning it is a non-functional remnant of the ribosomal protein L21 gene family. While the parent gene RPL21 encodes a ribosomal protein involved in the 60S subunit of eukaryotic ribosomes, RPL21P108 is a defective copy that does not produce a functional protein product. Processed pseudogenes like RPL21P108 are common throughout the genome and typically result from reverse transcription and integration of mRNA transcripts. RPL21P108 has no known biological function, is not a therapeutic target, and is generally not of clinical or pharmacological interest[5][8].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 108 (RPL21P108).